Current status and research progress of interventional and systemic therapy for advanced hepatocellular carcinoma
10.3760/cma.j.cn371439-20230805-00142
- VernacularTitle:中晚期肝细胞癌介入及系统治疗的现状与研究进展
- Author:
Shaoping LIU
1
;
Hanchuan LUO
;
Shuhan LIN
;
Jiahui LUO
Author Information
1. 广西壮族自治区贵港市人民医院肝胆外科，贵港 537100
- Keywords:
Carcinoma, hepatocellular;
Molecular targeted therapy;
Immune checkpoint inhibitors;
Interventionaltherapy
- From:
Journal of International Oncology
2023;50(12):758-762
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma (HCC) is a common malignant tumor with high incidence and mortality rates in China. Most patients are diagnosed at an advanced stage when seeking medical treatment. Interventional therapy is the main local treatment for HCC. As a new interventional material, CalliSpheres drug-eluting microspheres have more advantages than iodipin in traditional transcatheter chemoembolization, and hepatic artery infusion chemotherapy has higher rates of remission and translation. A series of targeted drugs, such as lenvatinib, donafinib, and apatinib have been approved for application in the treatment of advanced HCC. Immune checkpoint inhibitors have made breakthroughs in the treatment of advanced HCC. Various new drugs are emerging, with clinical studies on various combinations of different therapeutic drugs being gaining new findings. This article aims to discuss the recent applications and clinical research progress of interventional therapy, targeted therapy and immunotherapy in the treatment of advanced HCC so as to provide a reference for the decision-making of HCC.
